CAB LA + RPV LA clinical trials

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

This study looks at a new long-acting medicine for people with HIV whose current treatment isn't fully controlling the virus. It checks how well it works and if it's safe. We also want to know what patients think about it.